{"filings":[{"id":1619318,"accession_number":"0001140361-26-028368","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-07-14T11:30:53+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).","Full year pro forma net sales $320.2M (+9.4%); GAAP net loss $36.7M ($0.88 loss per share); adjusted EBITDA $13.2M.","FY2027 guidance: net sales $336M-$341M, Med Tech growth 12-15%, adjusted EBITDA $13M-$16M, adjusted EPS ($0.29)-($0.24).","Clinical milestones: FDA IDE approvals for APEX-Return, PAVE, RELIEF studies; Palmetto GBA LCD for NanoKnife IRE in prostate/liver cancer.","Ended FY2026 with $53.9M cash, debt-free; tariff headwinds $4.8M in FY2026, expected similar in FY2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91867,"accession_number":"0001140361-26-016424","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics files patent infringement suit against Endovascular Engineering over Hēlo Thrombectomy System","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed patent infringement lawsuit against Endovascular Engineering on April 23, 2026 in Delaware District Court.","Alleges E2's Hēlo Thrombectomy System infringes patents on self-expanding funnel technology for thrombus removal.","Complaint seeks damages and equitable relief for unauthorized use of AngioDynamics' protected features.","AngioDynamics states vigorous IP protection supports continued innovation and improved patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91866,"accession_number":"0001140361-26-012891","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.","GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.","Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).","Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.","Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":233567000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102257,"accession_number":"0001140361-26-003518","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.","Equity awards to accelerate vesting at Separation of Service Date; performance-based RSUs remain eligible to vest.","Retention awards: CFO Stephen Trowbridge and three other NEOs get 150% base salary; Lawrence Weiss gets 50%.","Retention conditions: remain employed until 6 months after new CEO starts or June 1, 2027.","Non-compete extended to 24 months; Clemmer releases all claims in exchange for transition benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102256,"accession_number":"0001140361-26-001154","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics CEO presents at J.P. Morgan conference; slide content not disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["President & CEO Jim Clemmer presented at J.P. Morgan 44th Annual Healthcare Conference on Jan 14, 2026.","Presentation slides furnished as Exhibit 99.1 but not reproduced in the filing; specific details unavailable.","No financial results, guidance changes, or material events contained in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102255,"accession_number":"0001140361-26-000341","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.","Raised FY26 net sales guidance to $312-314M (from $308-313M); Adj. EBITDA raised to $8-10M (from $6-10M).","CEO Jim Clemmer to retire in FY2027; board initiates search; Q2 generated $4.7M cash, debt-free balance sheet.","FDA IDE approvals for APEX-Return (AlphaVac blood management) and PAVE (AngioVac right-sided endocarditis) studies.","Federal Circuit affirmed Bard patent invalidation, eliminating $3M contingent payment obligation from prior settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":155144000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118552,"accession_number":"0001140361-25-041542","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AngioDynamics shareholders elect two Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James C. Clemmer and Michael E. Tarnoff, MD elected as Class I directors with ~29.6M and ~29.2M votes for.","Ratification of Deloitte & Touche as independent auditor for FY2026 approved: 35.7M for, 156.9K against.","Advisory vote on executive compensation approved: 28.4M for, 2.1M against, with 5.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118551,"accession_number":"0001140361-25-037060","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.","Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.","Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.","Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).","Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":75711000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135028,"accession_number":"0001140361-25-025835","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.","Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.","Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.","Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.","FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":292498000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151978,"accession_number":"0001140361-25-020621","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AngioDynamics enters $25M secured revolving credit facility with JPMorgan Chase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured $25 million revolving credit facility from JPMorgan Chase, maturing May 28, 2027.","Borrowing base based on working capital assets; initially subject to $5M availability block until fixed charge coverage ratio >1.10:1.00.","Interest: Term SOFR + 2.00% or ABR + 1.00%, commitment fee 0.20% on unused portion.","Proceeds for general corporate needs and working capital, including during manufacturing transfer.","Company states it remains well capitalized with cash on hand; facility provides incremental flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151977,"accession_number":"0001140361-25-011779","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics hosts virtual Cardiovascular Investor Event on April 2, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Event presentation slides furnished as Exhibit 99.1, but no specific financial or operational updates disclosed in filing.","Company focuses on cardiovascular technologies; no material new data or guidance provided.","Forward-looking statements caution about risks including competition, regulatory approvals, and economic conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151976,"accession_number":"0001140361-25-011767","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.","GAAP net loss $4.4M ($0.11 loss per share); adjusted loss $0.08 per share; adjusted EBITDA $1.3M vs -$3.6M a year ago.","FY2025 guidance raised: net sales $285-288M, Med Tech growth 14-16%, gross margin 53-54%, adjusted EBITDA $4-5M, adjusted EPS loss $(0.31)-(0.34).","Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation; initiated AMBITION BTK RCT for Auryon.","Secured $25M revolver commitment from J.P. Morgan for working capital flexibility; expects positive operating cash flow in Q4."],"consensus_eps_estimate":-0.1199,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":212340000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170817,"accession_number":"0001140361-25-001285","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics CEO presents at J.P. Morgan conference; no material financial updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["James Clemmer, President & CEO, presented at J.P. Morgan 43rd Annual Healthcare Conference on Jan 16, 2025.","Exhibit 99.1 contains only slide title page; no specific financial data, guidance, or operational updates provided.","No material new information disclosed; presentation appears routine investor relations activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170816,"accession_number":"0001140361-25-000538","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics hosts NanoKnife IRE Prostate event; no material financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual investor event on NanoKnife IRE for prostate held January 8, 2025.","Presentation slides provided but contain no new financial results or guidance.","Forward-looking statements caution about competition, regulatory, and clinical risks.","No changes to business outlook or material developments disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170815,"accession_number":"0001140361-25-000535","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).","GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.","Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.","Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).","Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2."],"consensus_eps_estimate":-0.1224,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":140336000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187785,"accession_number":"0001140361-24-047071","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AngioDynamics shareholders approve all proposals at 2024 annual meeting including equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class III directors: Burgess, Johnson, Licitra each with >24.8M votes for, 5.99M broker non-votes.","Ratified Deloitte & Touche as FY2025 auditor with 34.1M for, 155k against, 16.5k abstain.","Advisory approval of exec compensation: 26.0M for, 1.25M against, 1.04M abstain, 5.99M broker non-votes.","Approved amended 2020 Equity Incentive Plan increasing share reserve: 23.2M for, 5.06M against, 35k abstain, 5.99M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187784,"accession_number":"0001140361-24-042652","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).","Med Device segment sales $39.5M (-3.6% YoY); U.S. Med Device grew 2.1%.","GAAP net loss $12.8M ($0.31 loss/share); adjusted net loss $4.4M ($0.11 loss/share).","Submitted NanoKnife PRESERVE study to FDA for 510(k) prostate tissue indication; received CE Mark for Auryon in Europe.","FY2025 guidance reaffirmed: net sales $282-288M, adj. EBITDA loss $2.5M-$0, adj. EPS loss $0.38-$0.42."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":67491000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204289,"accession_number":"0001140361-24-033242","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.","GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.","FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.","Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.","Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":303914000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204288,"accession_number":"0001140361-24-033240","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.","Pro forma adjusted net loss improved to $6.5M ($0.16 loss per share) from $5.4M ($0.14 loss) in Feb 2023.","Pro forma net sales for continuing ops were $66.0M, down 6.9% as reported but up 8.0% constant currency vs prior year.","Med Tech segment pro forma sales grew 13.0% to $25.7M; Med Device segment pro forma sales down 14.7% as reported.","Pro forma adjusted EBITDA loss narrowed to $3.6M from $1.5M in the year-ago quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":303914000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221043,"accession_number":"0001140361-24-017807","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.","Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.","Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).","Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.","FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":232934000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221042,"accession_number":"0001140361-24-016977","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.","Minimum annual payments of $2.5M for six years through Feb 2029; additional payments based on 6% of port product net sales.","Contingent $3M payment due if Federal Circuit reverses invalidity findings in pending appeal (CAFC No. 23-2056).","Cross-licenses granted: BD licenses certain port patents to AngioDynamics; AngioDynamics licenses certain catheter patents.","Mutual covenants not to sue and releases; no admission of misconduct or liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240620,"accession_number":"0001140361-24-007427","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AngioDynamics appoints new Audit and Governance chairs; director class rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wesley Johnson appointed as new chair of the Audit Committee.","Jan Stern Reed appointed as new chair of the Nominating, Compliance and Corporate Governance Committee.","James Clemmer resigned as Class II director and re-appointed as Class I director to rebalance board classes.","Changes follow retirement of Dennis Meteny from Board and all committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240619,"accession_number":"0001140361-24-002997","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AngioDynamics director Dennis Meteny to retire Jan 31, 2024; board reduced to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dennis Meteny to retire from Board and as chair of Audit Committee, effective Jan 31, 2024.","Meteny served on Board since 2004; retirement not due to any disagreement with Company.","Board will not appoint replacement; size reduced from 9 to 8 directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240618,"accession_number":"0001140361-24-001849","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).","Q2 FY24 pro forma revenue $79.1M, growth 2.7%; Med Tech +3.5%, Auryon sales $11.4M (+12.9% YoY).","PRESERVE (NanoKnife) and APEX AV (AlphaVac PE) studies fully enrolled; FDA submission for PE planned early 2024.","Cumulative Auryon sales exceeded $100M; CE Mark for Auryon and AlphaVac expected 1H 2024.","Full-year adjusted EPS profitability expected in FY27; manufacturing restructuring to fully outsourced model initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":157752000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240617,"accession_number":"0001140361-24-000830","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share","Initiated restructuring to fully outsource manufacturing; expects $15M annualized cost savings by FY27","David D. Helsel, SVP of Global Operations and R&D, resigns effective Jan 12, 2024 (no disagreement)","Completed enrollment in APEX-AV trial for acute intermediate-risk pulmonary embolism using AlphaVac F18","Revised FY2024 guidance: net sales $320-$325M, gross margin 49-51%, adjusted loss per share $0.35-$0.42"],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":157752000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258123,"accession_number":"0001140361-23-053522","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AngioDynamics shareholders approve amended equity plan and elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four board nominees elected with votes ranging from 23.6M to 25.9M for; avg 24.7M for, 1.9M withheld.","Amended 2020 Equity Incentive Plan approved with 24.1M for and 2.5M against (excl. 5.8M broker non-votes).","Advisory say-on-pay approved with 24.4M for, 2.2M against; annual frequency vote also passed.","Ratification of Deloitte & Touche as auditor for FY ending May 31, 2024: 32.4M for, 11K against.","Company will hold advisory say-on-pay votes annually until next required frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258122,"accession_number":"0001140361-23-046804","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.","GAAP net income $45.9M ($1.15 EPS) includes $47.8M gain from Dialysis/BioSentry sale; adjusted loss $(0.12)/share.","Completed sale of Dialysis & BioSentry to Merit Medical for $100M cash; proceeds used to extinguish debt.","Reaffirmed FY2024 outlook: net sales $328-333M, gross margin ~50-52%, adjusted EPS loss $(0.28)-(0.34).","Cash & equivalents $57.6M at Aug 31, 2023, up from $44.6M at May 31, 2023; debt-free post-divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":78679000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275433,"accession_number":"0001140361-23-035863","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board adds Lorinda Burgess; director equity grants fully vested","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lorinda Burgess appointed as Class III director effective July 19, 2023, expanding board to nine members.","Burgess brings 35+ years experience, including 15+ years at Medtronic as Vice President of Finance, Americas Region.","Burgess was appointed to the Audit Committee and Compensation Committee of the Board.","Non-employee director annual equity grants changed to be fully vested at time of grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275432,"accession_number":"0001140361-23-034123","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.","GAAP net loss $21.5M ($0.54/share) includes $14.5M goodwill impairment from divestiture of Dialysis/BioSentry to Merit Medical for $100M cash.","FY2024 guidance: net sales $328-333M; gross margin 50-52%; adjusted loss per share $0.28-$0.34.","Pro forma revenue for FY23 (ex-divested businesses) was $306.3M; adjusted loss $0.43/share.","Subsequent to quarter end, used divestiture proceeds to extinguish $50M debt; cash $44.6M at May 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":338752000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292936,"accession_number":"0001140361-23-029854","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["1.01","1.02","2.01","9.01"],"status":"ready","headline":"AngioDynamics sells dialysis & biopsy product portfolio to Merit Medical for $100M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed June 8, 2023; proceeds used to repay ~$49.8M in debt under credit agreement, terminating it.","Estimated net cash proceeds of $46.8M after transaction costs and debt payoff.","Sold business contributed $23.7M revenue (9mo Feb 2023) and $27.7M (FY2022); pro forma operating loss increased ~$12.7M and ~$14.9M.","Company entered transition services and contract manufacturing agreements; five-year non-compete on sold business.","Pro forma balance sheet shows cash rising to $76.9M and long-term debt eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292935,"accession_number":"0001140361-23-028985","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AngioDynamics sells dialysis product portfolio and BioSentry to Merit Medical for $100M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal includes DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT, Vaxel Plus catheters and BioSentry biopsy product.","Divested portfolio contributed approximately $32M in sales in FY2023.","Net proceeds will be used to eliminate existing debt and fund strategic growth investments.","Transaction is dilutive to adjusted EPS and slightly dilutive to corporate gross margins.","Preliminary FY2023 net sales in the range of $338M to $339M; full results due early July."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292934,"accession_number":"0001140361-23-027896","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics wins court ruling invalidating three Bard patents in Delaware litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District Court granted AngioDynamics' Renewed Judgment as a Matter of Law on June 1, 2023.","Three U.S. patents (8,475,417; 8,545,460; 8,805,478) declared invalid as anticipated, indefinite, and ineligible.","Court also found no willful infringement by AngioDynamics.","Bard may appeal the ruling to the Federal Circuit; AngioDynamics believes it supports defenses in other pending cases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292933,"accession_number":"0001140361-23-018553","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics management to present at Needham conference; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Jim Clemmer and CFO Stephen Trowbridge to present at 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.","Presentation slides furnished as Exhibit 99.1 contain forward-looking statements and standard risk factors.","No specific financial results, guidance updates, or material events announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313596,"accession_number":"0000914121-23-000149","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 net sales up 9% but guides down; adjusted EPS loss $0.03 vs prior guidance for profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.","Med Tech sales $22.9M (+16.6%); Auryon +42.8% to $10.4M; AngioVac -15.7% to $5.5M.","Gross margin 50.2%, down 200 bps YoY; adjusted EBITDA $4.3M vs $6.7M.","FY2023 guidance cut: net sales now $338-342M (from $342-348M); adjusted EPS now loss $0.06 to loss $0.01 (from profit $0.01-0.06).","Cash $30.1M; total debt $50M; generated $1.4M operating cash in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":247678000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313595,"accession_number":"0000914121-23-000145","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics presents at Raymond James conference; no material new information in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Jim Clemmer and CFO Stephen Trowbridge presented at Raymond James 44th Annual Institutional Investors Conference on March 6, 2023.","Presentation slides furnished as Exhibit 99.1, but full content not included in the provided filing text.","No specific financial guidance, earnings, or material updates disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313594,"accession_number":"0000914121-23-000135","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics SVP, General Counsel and Secretary Richard Rosenzweig resigns effective Feb 27, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard C. Rosenzweig resigned as SVP, General Counsel and Secretary effective February 27, 2023.","Rosenzweig is leaving to join Dentsply Sirona Inc. to work with a long-time colleague.","No replacement has been named; CEO James Clemmer expressed best wishes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313593,"accession_number":"0000914121-23-000011","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics presents at J.P. Morgan Healthcare Conference; no specifics available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Jim Clemmer and CFO Stephen Trowbridge presented at 41st Annual J.P. Morgan Healthcare Conference on Jan 12, 2023.","Presentation slides furnished as Exhibit 99.1 but not reproduced in this filing excerpt.","Slide content is not available; no financial guidance or material updates can be extracted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313592,"accession_number":"0000914121-23-000003","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 FY2023 sales $85.4M (+9.1% YoY); GAAP loss $0.21/sh, adj EPS $0.01; reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M.","GAAP net loss $0.21 per share; adjusted EPS $0.01 vs adjusted loss $0.02 a year ago.","Adjusted EBITDA $7.5M, up from $4.4M in prior-year quarter.","FY2023 guidance reaffirmed: net sales $342-348M, gross margin ~52.5-54.5%, adj EPS $0.01-$0.06.","Cash $29.9M, $50M in debt; Preserve prostate cancer study enrollment passed midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":166966000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332064,"accession_number":"0001140361-22-043590","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics guides Q2 cash ~$28-30M; results due Jan 5, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected cash at Nov 30, 2022 (Q2 FY2023 end): $28-30 million.","Net cash increase of ~$3.5-5.5M from Q1 FY2023 end.","Cash guidance excludes $4.2M CARES Act receivable.","Q2 FY2023 earnings scheduled for release on or around Jan 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332063,"accession_number":"0001140361-22-042873","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics loses patent infringement jury verdict to Bard on port products","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury verdict found AngioDynamics' implantable port products infringe certain Bard patents (Nov 22, 2022).","Damages were bifurcated and not determined by jury; separate proceeding required.","Company strongly disagrees with verdict, believes it is unsupported, and plans post-trial motions and appeals.","Equitable issues and patent eligibility issues remain to be decided by the judge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332062,"accession_number":"0000914121-22-004127","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AngioDynamics shareholders approve amended equity plan and ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Meteny (33.3M for, 0.9M withheld) and Tarnoff (24.2M for, 10.0M withheld) as directors.","Ratified Deloitte as auditor (36.3M for, 35.7K against) and approved say-on-pay (33.3M for).","Approved amended 2020 Equity Plan (32.8M for, 1.4M against) and amended ESPP (34.1M for, 0.1M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332061,"accession_number":"0000914121-22-004106","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics loses antitrust jury verdict against C.R. Bard in PICC market","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Bard did not unlawfully restrain competition in U.S. PICC market following two-week trial in N.D.N.Y.","AngioDynamics 'disappointed' with outcome, considering appeal.","Verdict covers percutaneously inserted central catheters (PICCs), a vascular access device.","No monetary damages or financial impact disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332060,"accession_number":"0000914121-22-004104","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.","Med Tech net sales $22.8M (+29.6%), driven by Auryon (+50.0%) and thrombectomy (+31.8%); Med Device declined 1.1% to $58.7M.","Gross margin 51.9% down 20 bps; adjusted loss per share $0.06 vs $0.02 in prior year.","FY2023 guidance reaffirmed: net sales $342-348M, gross margin 52.5%-54.5%, adjusted EPS $0.01-$0.06.","New $75M credit facility with $30M term loan (drawn $25M); cash $24.6M; AlphaVac F18 full market release commenced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":81537000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349534,"accession_number":"0000914121-22-004083","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-08-31T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"AngioDynamics enters $105M credit facility; repays existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $75M secured revolving credit facility maturing 2027, plus $30M term loan facility for Auryon laser manufacturing costs.","Used to repay all amounts under prior credit agreement (dated June 3, 2019), which was terminated.","Interest rates: SOFR plus margin tied to leverage ratio (1.25%-1.75% for SOFR loans).","Financial covenants: Fixed charge coverage >=1.25x, total leverage <=3.00x (3.50 after acquisitions).","Uncommitted expansion feature allows up to $75M additional in $5M increments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349533,"accession_number":"0000914121-22-004074","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics CFO presents at Canaccord conference; no new material disclosures in truncated exhibit","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Stephen Trowbridge, EVP & CFO, presented at Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022.","Presentation slides were furnished as Exhibit 99.1 but contain no specific financial data or updated guidance in the available text.","Filing includes standard forward-looking statements and risk factors; no earnings results or material events disclosed.","Exhibit text is truncated; no concrete numbers, targets, or strategic updates can be extracted from the provided portion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349532,"accession_number":"0000914121-22-004052","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q4 sales $87M (+13% YoY), GAAP EPS -$0.16; FY23 rev guide $342-348M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $87.0M (+13.2% YoY); Med Tech sales up 40% to $22.6M.","GAAP loss per share $0.16; adjusted EPS $0.01; full-year GAAP loss $0.68.","Full-year net sales $316.2M (+8.7% YoY); gross margin declined 150 bps to 52.4%.","FY2023 guidance: net sales $342-348M, gross margin 52.5-54.5%, adjusted EPS $0.01-$0.06.","Cash $28.8M at May 31; $25M drawn on revolver; operating cash flow $8.6M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":316219000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366508,"accession_number":"0000914121-22-002826","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 net sales $74.0M (+3.9% YoY); GAAP EPS -$0.13, adjusted $0.03; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.","Gross margin 52.2%, down 190bps YoY on inflation, labor, supply chain; net loss $5.0M ($0.13/sh) vs $3.5M loss prior year.","Adjusted EPS $0.03 (incl. $4.2M CARES Act benefit); adjusted EBITDA $6.7M vs $5.4M a year ago.","Reaffirmed FY2022 guidance: sales $310-315M, gross margin 52-54%, adjusted EPS -$0.02 to $0.02.","Post-quarter: FDA cleared AlphaVac F18 for venous use; IDE approved for pulmonary embolism; PRESERVE prostate trial enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":229221000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385957,"accession_number":"0000914121-22-000132","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics presents at Needham conference; no new financial guidance or material data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO James Clemmer and CFO Stephen Trowbridge presenting at 24th Annual Needham Virtual Growth Conference on Jan 10, 2022.","Presentation slides filed as Exhibit 99.1 contain no new financial projections or material non-public information.","No changes to previously issued guidance or business outlook; conference participation is routine investor engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385956,"accession_number":"0000914121-22-000084","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.","GAAP net loss $8.4M (-$0.21/share) vs loss $4.3M (-$0.11) a year ago; adjusted loss per share $0.02.","Gross margin 51.8%, down 340 bps due to supply chain, labor shortages, raw material/freight costs.","FY2022 revenue guidance reaffirmed $310-315M; gross margin cut to 52-54% from 55%; adj. EPS guidance to ($0.02)-$0.02.","Full market release of AlphaVac Thrombectomy device commenced after quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":155251000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403864,"accession_number":"0000914121-21-007590","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics begins full market release of AlphaVac F22 thrombectomy system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AlphaVac F22 mechanical thrombectomy system, 510(k) cleared, moves from limited to full market release.","Limited market release initiated mid-September 2021; full release commenced December 6, 2021.","Product is designed for mechanical thrombectomy in vascular applications.","Full market release expands commercial availability to broader customer base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-06T23:59:59+00:00|403864"}